Walvax Biotechnology Co., Ltd. is a modern biological enterprise, specializing in the R&D, manufacture and marketing of biological products and vaccine. With leading technology, we focus on providing safe and effective vaccine products for human use. Our company was founded in 2001 and is located in Kunming, Yunan Province of China. We have more than 500 employees, including about 110 technicians in the R&D. There is a leading R&D centre of pilot plant test base for vaccine innovation located in Kunming. Walvax has two modern manufacture bases named as Yuxi Walvax and Jiangsu Walvax, and our marketing network covers 31 provinces and more than 2,000 counties and areas in the country.

Relying on advanced technology and innovation ability, Walvax undertakes several national projects and is named as "National Vaccine R&D Platform Centre". Walvax owns two demonstration bases for High-Tech Industrialization Projects authorized by National Development and Reform Commission and "International Science and Technology Cooperation Foundation" issued by National Science and Technology Ministry. Our company has already registered and applied thirteen varieties of vaccine to SFDA during last nine years of research. We received approval in 2007 for Haemophilus Influenzae Type B Conjugate Vaccine (HIB) and received approval in 2009 for Group AC Meningococcal Polysaccharide Conjugate Vaccine. We have a robust pipeline of new vaccine products under research and development. Our company is currently developing more than 15 kinds of new vaccine in various stages.

One of our manufacture bases, Yuxi Walvax, is located in Yuxi High-Tech Industrial Zone, with total coverage of 84,000 square meters. The total production facility of Yuxi Walvax is over 38,000sqm. The HIB conjugate vaccine production line and Group A, C meningococcal conjugate vaccine production line were built entirely according to SFDA GMP standard. The production capacity is 50 million doses annually. The new vaccine production line will be completed later this year and increase production ability to 64 million doses annually.

We focus on providing Chinese citizens with affordable and international quality vaccines while pursuing the opportunities to provide our vaccines for people worldwide. Importantly, Walvax has the fully integrated human vaccine research and development expertise and manufacturing capability necessary to support the pipeline of potential new vaccines. According to SFDA GMP requirements, Walvax has strict control on working staff members, plant environment, facilities, raw materials, hygiene, validation, documentation, manufacture process, quality control, product selling, after sales service and harm vigilance, and we have timely training for staff to guarantee fine running of the whole quality assurance system and good quality of finished products.

To provide safe, effective and technology leading vaccine products and a high quality service system, "Let everyone be born healthy and enjoy the happiness of the life" is Walvax's mission.